Related Experiment Video
Updated: Jan 11, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
Intrapartum Glycemic Control and Clinical Outcomes
Ghamar Bitar1, Michal Fishel Bartal1,2
1Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.
Diabetes Spectrum : a Publication of the American Diabetes Association
|November 19, 2025
Summary
Strict blood glucose control during pregnancy for women with diabetes is recommended, but evidence linking it to improved neonatal outcomes is limited. Further research is needed to confirm these associations.
Area of Science:
- Obstetrics and Gynecology
- Endocrinology
- Neonatal Medicine
Background:
- Current guidelines recommend strict intrapartum glycemic control for pregnant individuals with diabetes.
- This approach aims to optimize both maternal and neonatal health outcomes.
- However, the strength of evidence supporting this link is not well-established.
Purpose of the Study:
- To evaluate the association between strict maternal blood glucose control during pregnancy and neonatal outcomes.
- To critically assess the existing evidence base for current recommendations.
Main Methods:
- Review of current clinical recommendations.
- Analysis of existing evidence on maternal glycemic control and neonatal outcomes in diabetes in pregnancy.
Main Results:
- Established evidence is limited in demonstrating a strong association.
- The link between strict maternal blood glucose control and neonatal outcomes requires further investigation.
Conclusions:
- While recommended, the evidence supporting strict intrapartum glycemic control for optimizing neonatal outcomes in diabetes in pregnancy is not robust.
- Further research is necessary to clarify the benefits and establish definitive associations.
More Related Videos
Related Concept Videos
01:20Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:15Hypoglycemia and Glucagon
779
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
779
01:15Diabetes: Management and Pharmacotherapy
851
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
851
01:16Insulin: Dosing Regimen and Adverse Effects
663
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
663
01:06Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573